The Global Rivaroxaban
Market, by Strength (10 mg, 15 mg, and 20 mg), by Application (Deep Vein
Thrombosis Prophylaxis and Pulmonary Embolism), by Distribution Channel
(Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region
(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
is estimated to be valued at US$ 5,653 million in 2017 and is projected to
exhibit a CAGR of 1.5% over the forecast period (2018 – 2026). The API patent
is set to expire in 2020 and product patent in 2023 leading to anticipated
price erosion if the drug. Rivaroxaban is an oral anticoagulant, which was
developed by Bayer and sold under the brand name Xarelto. The drug is indicated
for the treatment of deep vein thrombosis prophylaxis or pulmonary embolism and
to reduce the risk of stroke and systemic embolism in patients with non-valvular
atrial fibrillation (AF).
The drug is marketed by Bayer
outside the U.S. and in the U.S., it is marketed by Janssen Pharmaceuticals,
Inc. Xarelto is among the most popular anticoagulants, which includes brands
like Caumadin, Praxada, and Eliquis. The trajectory growth of rivaroxaban
market can be attributed to increasing clinical trials by companies and
universities to expand the indication of the drug or to use in combination with
other drug. For instance, the University Hospital Inselspital, Berne, in
collaboration with Bayer and Janssen, and two others, are studying the efficacy
of rivaroxaban in patients undergoing bariatric surgery and as on May 2018, the
trial was under phase II.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1962
Browse Market Data 22 Tables and
20 Figures spread through 150 Pages and in-depth TOC on ‘Rivaroxaban Market, by
Strength (10 mg, 15 mg, and 20 mg), by Application (Deep Vein Thrombosis
Prophylaxis and Pulmonary Embolism), by Distribution Channel (Hospitals
Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region - Global
Forecast to 2026’ To know the latest trends and insights related to rivaroxaban
market,
The market players of rivaroxaban
market are also concentrating on enhancing effectiveness and reducing the side
effects such as bleeding of the drug. For instance, as of June 2018, Janssen
Scientific Affairs, LLC is studying the effectiveness of Xarelto with a mobile
adherence platform, to improve medication adherence in patients with atrial
fibrillation. However, the presence of cheaper alternative drugs such as
warfarin, apixaban, and dabigatran are expected to be major factors hindering the
rivaroxaban market growth. The treatment cost using warfarin is as low as US$ 4
per month whereas the cost of rivaroxaban is around US$ 450 per month. This
vast difference in cost of the drug lead the patients towards adopting cheaper
alternative, thereby negatively affecting the market growth.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/rivaroxaban-market-1962
Key takeaways of the Rivaroxaban
Market:
The global rivaroxaban market is
expected to expand at a CAGR of 1.5% over the forecast period (2018 – 2026),
owing to increasing clinical trials
High cost of rivaroxaban therapy
compared to it alternatives may restrain the market growth
Patent expiration leading to
manufacturing of generics is expected to pose challenge to the Xarelto brand
and may result in price reduction
Some of the major players
operating in the global rivaroxaban market include Janssen Pharmaceuticals Inc.
and Bayer AG.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1962
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment